RxDoctor Payments Data

George Burgess

Family · Texarkana, TXNPI 1376847210

Payments from drug & device makers

$13,693in general payments, 2019–2025

Across 534 payments — averaging $25.64 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Inspire Medical Systems, Inc.$2K
  • ZOLL Respicardia, Inc.$1K
  • GSK$1K
  • AstraZeneca$1K
  • United Therapeutics Corporation$881
  • Boehringer Ingelheim$878
  • plus $6K from 33 others

What the payments were for

  • Travel & lodging$1,69912%
  • Food & beverage$11,59485%
  • Education$4013%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$13,693 in reported general payments places this provider in the 95th percentile of 15,456 family providers in Texas.

See all family providers in Texas

Medicare billing

Part B allowed, 2024
$123,176
Medicare patients
869
Services billed
1,966

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter384$294,777
Breztri AerosphereBudesonide/Glycopyr/Formoterol91$80,688
Breo ElliptaFluticasone/Vilanterol132$76,082
Stiolto RespimatTiotropium Br/Olodaterol Hcl35$19,959
SunosiSolriamfetol Hcl13$11,359
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr21$10,695
SymbicortBudesonide/Formoterol Fumarate24$9,283
Spiriva RespimatTiotropium Bromide13$7,607
Albuterol Sulfate HfaAlbuterol Sulfate143$4,033
Levalbuterol Tartrate HfaLevalbuterol Tartrate25$2,322
Roflumilast38$2,150
Fluticasone-SalmeterolFluticasone Propion/Salmeterol14$1,854
Armodafinil20$1,625
Wixela InhubFluticasone Propion/Salmeterol13$1,164
Ventolin HfaAlbuterol Sulfate19$1,079

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta$1,335$381,554537 claims
AstraZenecaBreztri Aerosphere, Symbicort$1,131$89,971115 claims
Boehringer IngelheimStiolto Respimat, Spiriva Respimat$878$27,56648 claims
Axsome Therapeutics, Inc.Sunosi$175$11,35913 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 15,456 family providers in Texas.

Other family in Texarkana

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →